• MediPharm Labs reported positive Phase II LiBBY trial results for its oral cannabinoid formulation in agitation tied to advanced dementia.
• Trial met its primary endpoint, showing statistically significant improvement versus placebo at week 2 on the Cohen-Mansfield Agitation Inventory.
• Benefits held through the 12-week double-blind period; open-label extension data indicated sustained response.
• Company is reviewing full results, weighing regulatory steps, further clinical development, potential strategic collaborations.
• MediPharm retains ownership of the formulation, related IP, study data rights; pursuing patent filings tied to the trial outcome.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MediPharm Labs Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607140835PRIMZONEFULLFEED9761823) on July 14, 2026, and is solely responsible for the information contained therein.